Evotec has a very strong background in anti-infective drug discovery; leveraging an exceptional in vitro and in vivo biology knowledge in anti-infectives and a comprehensive portfolio of assays, amenable to high throughput screening for hit discovery for new infectious disease therapies. Our team provides full microorganism screening capabilities against BSL2 and BSL3 biological agents.
Microorganism High Throughput Screening Capabilities
Micro-organism screening capabilities include:
- Recombinant human cells or primary cells
- Micro-organisms: bacteria, viruses, and yeast & fungi
Read-out technologies include:
- Absorbance
- Luminescence
- Fluorescence
- HTRF
- High-content imaging
- RT-qPCR
Screening assay principles in 384-well and 1536-well plate formats include:
- Phenotypic assays on growth inhibition of micro-organisms and cells
- Target-based assays: biochemical assays, cellular assays with gene reporter and cell-based assays with the incubation of cells and pathogen
